ursodeoxycholic acid has been researched along with Disease Exacerbation in 144 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 9 (6.25) | 18.2507 |
| 2000's | 42 (29.17) | 29.6817 |
| 2010's | 72 (50.00) | 24.3611 |
| 2020's | 21 (14.58) | 2.80 |
| Authors | Studies |
|---|---|
| Abdelaziz, AE; Abdelkawy, KS; Ali, AA; Elbarbry, F; Fouda, A; Hussien, M | 1 |
| Mankongpaisarnrung, C; McCashland, TM; Olivera-Martinez, MA; Rajendiran, G | 1 |
| Aspinall, RJ; Berg, CP; Boudes, P; Bowlus, CL; Choi, YJ; Dörffel, Y; Galambos, MR; Goel, A; Gordon, SC; Harrison, SA; Hirschfield, GM; Jones, DEJ; Kremer, AE; Levy, C; Mayo, MJ; McWherter, CA; Neff, GW; Sheridan, DA; Shiffman, ML; Stanca, CM; Steinberg, A; Swain, MG; Thuluvath, PJ; Vierling, JM | 1 |
| Hussain, N; Trivedi, PJ | 1 |
| Fickert, P; Wagner, M | 1 |
| Lee, HW; Lee, JI; Lee, KS | 1 |
| Bruns, T; Carbone, M; Corpechot, C; Dalekos, GN; Floreani, A; Gatselis, NK; Gulamhusein, A; Hansen, BE; Hirschfield, GM; Invernizzi, P; Janssen, HLA; Kowdley, KV; Lammers, WJ; Lindor, KD; Maria Battezzati, P; Mason, AL; Mayo, MJ; Murillo Perez, CF; Nevens, F; Parés, A; Ponsioen, CY; Thorburn, D; Trivedi, PJ; van der Meer, A; Verhelst, X | 1 |
| Bowlus, C; Gao, L; Gershwin, ME; He, X; Leung, PSC; Wang, L; Woo, E; Yang, G | 1 |
| Kowdley, KV; Shah, RA | 1 |
| Fan, X; Lu, C; Ma, Y; Men, R; Ni, P; Si, T; Yang, L | 1 |
| Gulamhusein, AF; Hirschfield, GM | 1 |
| Chascsa, DMH; Lindor, KD | 1 |
| Dyson, JK; Jones, D; Phaw, NA | 1 |
| de Veer, RC; Laschtowitz, A; Schramm, C; Van der Meer, AJ | 1 |
| Bentow, C; Garcia, M; Mahler, M; Norman, GL; Pares, A; Reig, A; Romera, MA; Ruiz-Gaspà, S; Shums, Z; Vinas, O | 1 |
| Atkin, SL; De Vincentis, A; Jamialahmadi, T; Mahjoubin-Tehran, M; Mantzoros, CS; Mikhailidis, DP; Sahebkar, A | 1 |
| Anton, A; Appleby, M; Bandmann, O; Buckley, E; Foltynie, T; Hoggard, N; Jenkins, T; Maru, S; Mazza, C; McNeill, A; Moll, S; Payne, T; Sassani, M; Taylor, R; Wilkinson, ID | 1 |
| Han, Y; Liu, Y; Ma, S; Sun, K; Tian, S; Wang, L; Zhang, M; Zhou, X | 1 |
| Bergquist, A; Beuers, U; Drebber, U; Färkkilä, M; Greinwald, R; Hirschfield, GM; Kupcinskas, L; Manns, MP; Ott, P; Parés, A; Poupon, R; Pröls, M; Spengler, U; Stiess, M; Wendum, D | 1 |
| Fan, X; Huang, C; Liu, Y; Shen, M; Xiang, X; Yang, L; Yang, X | 1 |
| Chang, G; Chen, S; Guo, Z; Huang, K; Li, Z; Liu, C; Liu, R; Peng, M; Su, Q | 1 |
| De Martin, S; Floreani, A | 1 |
| Agostinho, C; Alexandrino, G; Alves, AL; Andreozzi, V; Banhudo, A; Calinas, F; Carvalho, J; Coelho, M; Cortez-Pinto, H; Cotrim, I; Dias, T; Figueiredo, P; Gomes, MV; Gouveia, C; Leal, C; Liberal, R; Lopes, S; Loureiro, R; Machado, MV; Maia, L; Martins, A; Mesquita, M; Nunes, J; Oliveira, J; Pedroto, I; Pinto, JS; Presa, J; Santos, A; Vale, AHE | 1 |
| Gershwin, ME; Tanaka, A | 1 |
| Hegade, VS; Jones, DEJ; Wong, LL | 1 |
| Alvaro, D; Canonico, PL; Carbone, M; Craxi, A; Floreani, A; Gardini, I; Gasbarrini, A; Invernizzi, P; Kruger, P; Lanati, E; Marzioni, M; Mennini, FS; Muratori, L; Ronco, V; Vespasiani Gentilucci, U | 1 |
| Floreani, A; Mangini, C | 1 |
| Lindor, KD; Silveira, MG | 2 |
| Burman, BE; Jhaveri, MA; Kowdley, KV | 1 |
| Parés, A; Reig, A; Sesé, P | 1 |
| Battezzati, PM; Bruns, T; Corpechot, C; Dalekos, GN; Floreani, A; Goet, JC; Hansen, BE; Harms, MH; Hirschfield, GM; Invernizzi, P; Janssen, HLA; Kowdley, KV; Lammers, WJ; Lindor, KD; Mason, AL; Mayo, MJ; Nevens, F; Parés, A; Ponsioen, CY; Thorburn, D; van Buuren, HR; Verhelst, X | 1 |
| Alexander, GJM; Chapman, MH; Collier, J; Dyson, JK; Hirschfield, GM; Hübscher, S; Jones, DEJ; Patanwala, I; Pereira, SP; Thain, C; Thorburn, D; Tiniakos, D; Walmsley, M; Webster, G | 1 |
| Corrigan, M; Jones, D; Jopson, L; Khanna, A; Peterson, P; Rudell, E | 1 |
| Díaz Ramírez, GS; Donado Gómez, JH; Marín Zuluaga, JI; Martínez Casas, OY; Muñoz Maya, O; Restrepo Gutiérrez, JC; Santos, Ó | 1 |
| Goel, A; Kim, WR | 1 |
| Aguilar, MT; Carey, EJ | 1 |
| Ben Mansour, W; Bouhlel, W; Guediche, A; Jemmali, D; Loghmari, MH; Safer, L | 1 |
| Aguilera, L; Albillos, A; Martínez, J | 1 |
| Alexander, GJ; DiBello, J; Fisher, H; Gilchrist, K; Hegade, VS; Hirschfield, GM; Jones, DEJ; Kendrick, S; Mells, GF; Sandford, RN | 1 |
| Gong, JY; Lu, Y; Setchell, KD; Wang, JS; Zhang, MH; Zhao, J | 1 |
| Khan, MN; Middleton, JP; Niccum, M; Syed, S; Vergales, BD | 1 |
| Battezzati, PM; Corpechot, C; Floreani, A; Hansen, BE; Harms, MH; Hirschfield, GM; Invernizzi, P; Janssen, HLA; Kowdley, KV; Lammers, WJ; Lindor, KD; Mason, AL; Mayo, MJ; Nevens, F; Parés, A; Ponsioen, CY; Thorburn, D; van Buuren, HR; van der Meer, AJ | 1 |
| Gaspar, R; Liberal, R; Macedo, G | 1 |
| Carey, EJ; Yokoda, RT | 1 |
| Aladağ, M; Alalkim, F; Beretta-Piccoli, BT; Berg, T; Bonder, A; Calişkan, AR; Chayanupatkul, M; Coppo, C; Demir, N; Efe, C; Eliasson, J; Eren, F; Fischer, J; Gönen, C; Günşar, F; Güzelbulut, F; Henriksson, I; Heurgué-Berlot, A; Kiyici, M; Lytvyak, E; Marschall, HU; Montano-Loza, AJ; Muratori, L; Muratori, P; Nilsson, E; Önnerhag, K; Ozaslan, E; Purnak, T; Rorsman, F; Schiano, TD; Semela, D; Taşçilar, K; Trivedi, H; Wahlin, S; Werner, M; Yoshida, EM; Ytting, H | 1 |
| Fan, X; Huang, C; Men, R; Ni, P; Shen, M; Wang, T; Yang, L | 1 |
| Chen, H; Shen, M; Shi, TY; Wang, L; Zhang, FC; Zhang, LN; Zhang, X | 1 |
| Bresson-Hadni, S; Efe, C; Heurgué-Berlot, A; Kav, T; Masi, C; Muratori, L; Muratori, P; Ozaslan, E; Purnak, T; Schiano, TD; Thiéfin, G; Torgutalp, M; Wahlin, S | 1 |
| Cassani, F; Fabbri, A; Granito, A; Lalanne, C; Lenzi, M; Masi, C; Menichella, R; Muratori, L; Muratori, P; Pappas, G; Quarneti, C | 1 |
| Imam, MH; Lindor, KD | 1 |
| Lohse, AW; Zenouzi, R | 1 |
| Harada, K; Kakuda, Y; Nakanuma, Y | 1 |
| Bunchorntavakul, C; Reddy, KR | 1 |
| Joshita, S; Kimura, T; Komatsu, M; Matsumoto, A; Ota, M; Sekiguchi, T; Shibata, S; Tanaka, E; Umemura, T; Usami, Y | 1 |
| Lindor, KD; Tabibian, JH | 1 |
| Battezzati, PM; Burroughs, AK; Caballeria, L; Cheung, A; Corpechot, C; Floreani, A; Hansen, BE; Harms, MH; Hirschfield, GM; Invernizzi, P; Janssen, HL; Kowdley, KV; Kumagi, T; Lammers, WJ; Lindor, KD; Lleo, A; Mason, AL; Mayo, MJ; Nevens, F; Parés, A; Ponsioen, CY; Poupon, R; Trivedi, PJ; van Buuren, HR | 1 |
| Braddock, M; Chen, YP; Huang, GQ; Lin, YQ; Shi, KQ; Wang, LR; Zheng, MH; Zhou, MT; Zhu, GQ | 1 |
| Castro, RE; Rodrigues, CMP | 1 |
| Ali, AH; Carey, EJ; Lindor, KD; Tabibian, JH | 1 |
| Beuers, UH; Boonstra, K; de Vries, EM; Geskus, RB; Leeflang, MM; Ponsioen, CY; Wang, J; Weersma, RK | 1 |
| Bruno, S; Carbone, M; Invernizzi, P; Mells, GF; Ronca, V | 1 |
| Carbone, M; Gershwin, ME; Invernizzi, P; Malinverno, F; Mousa, HS; Ronca, V | 1 |
| Li, G; Li, L; Li, Y; Xu, P; Yu, C | 1 |
| Bowlus, CL; Kenney, JT; Navarro, R; Rice, G | 1 |
| Lammert, F; Zimmer, V | 1 |
| He, P; Lei, JH; Wang, CX; Yuan, WG; Zhang, CY | 1 |
| Parés, A | 1 |
| Battezzati, PM; Crosignani, A; Invernizzi, P; Podda, M; Prina, E; Selmi, C | 1 |
| Boileau, R; Coté, J; Deslaurier, J; Huet, PM; Huet-van Kerckvoorde, J; Matsutami, S; Vincent, C | 1 |
| Dienes, HP; Frenzel, C; Galle, PR; Herkel, J; Kanzler, S; Kasper, HU; Lohse, AW; Lüth, S; Schramm, C | 1 |
| Alberts, DS; Hsu, CH; Long, Q; Taylor, JM | 1 |
| Abe, M; Azemoto, N; Hamada, M; Hiasa, Y; Matsuura, B; Murata, Y; Onji, M | 1 |
| Abe, K; Honma, F; Kanno, Y; Monoe, K; Ohira, H; Saito, H; Sakamoto, N; Takahashi, A; Yokokawa, H; Yokokawa, J | 1 |
| Boberg, KM; Karlsen, TH; Schrumpf, E | 2 |
| Lindor, KD; Sinakos, E | 1 |
| Alaggio, R; D'Antiga, L; Giordano, G; Guido, M; Riello, L; Zancan, L | 1 |
| Abdalian, R; Arenovich, T; Coltescu, C; Fischer, SE; Guindi, M; Heathcote, EJ; Hirschfield, GM; Kumagi, T | 1 |
| Bonder, A; Bonis, PA; Kaplan, MM; Ruthazer, R | 1 |
| Befeler, A; Keach, J; Kowdley, KV; Lindor, K; Marschall, HU; Sinakos, E | 1 |
| Lindor, K; Sinakos, E | 1 |
| Houwen, RH; Klomp, LW; Stapelbroek, JM; van de Graaf, SF; van der Woerd, WL; van Mil, SW | 1 |
| Juran, BD; Lazaridis, KN; Nguyen, DL | 1 |
| Antoniazzi, S; Baldo, V; Brombin, C; Caroli, D; Cazzagon, N; Chiaramonte, M; Floreani, A; Rizzotto, ER; Salmaso, L; Variola, A | 1 |
| Dong, XY; Han, Y; Han, ZY; Huang, XF; Li, ZS; Shi, YQ; Wang, JH; Wang, RA; Yan, W; Zhou, XM; Zhu, JY | 1 |
| Beraza, N; Bischoff, SC; Boekschoten, M; Ehedego, H; Mueller, M; Ofner-Ziegenfuss, L; Trauner, M; Trautwein, C | 1 |
| Colombo, C; Consonni, D; Costantino, L; Coviello, DA; Degiorgio, D; Maggiore, G; Motta, V; Tornillo, L; Vajro, P | 1 |
| Hansen, BE; Komárek, A; Kuiper, EM; Lesaffre, E; van Buuren, HR | 1 |
| Ambrosini, YM; Gershwin, ME; Ishibashi, H; Komori, A; Nakamura, M; Shimoda, S | 1 |
| Álvarez Ferre, J; González Jiménez, E; Schmidt Río-Valle, J | 1 |
| Chapman, RW; Culver, EL | 1 |
| Ponsioen, CY | 1 |
| Gotthardt, DN; Kloeters-Plachky, P; Kulaksiz, H; Rudolph, G; Schirmacher, P; Stiehl, A | 1 |
| Fauler, G; Fickert, P; Frank, S; Guelly, C; Gumhold, J; Höfler, G; Kratky, D; Lass, A; Magnes, C; Moustafa, T; Reicher, H; Sattler, W; Silbert, D; Sinner, F; Thueringer, A; Trauner, M; Zechner, R | 1 |
| Jorgensen, R; Lindor, KD; Momah, N; Silveira, MG; Sinakos, E | 1 |
| Chazouillères, O | 1 |
| Jacquemin, E | 2 |
| Chen, YS; Fan, LJ; Huang, CY; Huang, YL; Liao, HY; Lin, W; Liu, YM; Wang, SZ; Yan, HP | 1 |
| Chetwynd, A; James, OF; Metcalf, JV; Newman, W; Prince, M | 1 |
| Czaja, AJ | 1 |
| Bissonnette, M; Brasitus, T; Hart, J; Nguyen, L; Sitrin, MD; Stoiber, D; Wali, RK | 1 |
| Dietrich, CF; Faust, D; Fellbaum, C; Zeuzem, S | 1 |
| Chazouillères, O; Wendum, D | 1 |
| Hayem, G; Meyer, O; Pagnoux, C; Palazzo, E; Roux, F | 1 |
| Chazouillères, O; Heathcote, EJ; Lindor, KD; Parés, A; Poupon, R; Poupon, RE | 1 |
| Paumgartner, G | 1 |
| Burroughs, AK; Chan, CW; Goulis, J; Papatheodoridis, GV | 1 |
| Angulo, P; Burgart, L; Colin, P; Harrison, ME; Heathcote, EJ; Jorgensen, R; Kowdley, KV; Lindor, KD; Lymp, JF | 1 |
| Yamada, G | 1 |
| Dickson, ER; Kim, WR | 1 |
| Angulo, P; Lindor, KD | 1 |
| Bahr, A; Carrat, F; Chrétien, Y; Corpechot, C; Poupon, R; Poupon, RE | 1 |
| Burroughs, AK; Carpenter, JR; Chan, CW; Feudjo, M; Gunsar, F; Rigamonti, C; Vlachogiannakos, J | 1 |
| Eisebitt, R; Leuschner, U; Manns, MP | 1 |
| Beuers, U; Rust, C | 1 |
| Vierling, JM | 1 |
| Gondo, H; Harada, M; Hashiguchi, M; Higuchi, M; Imamura, R; Kato, K; Kuroiwa, M; Nagafuji, K; Ogata, H; Okamura, T; Oku, E; Ono, N; Otsubo, K; Sata, M; Seki, R; Shibuya, T; Taniguchi, S; Yakushiji, K; Yoshimoto, K | 1 |
| Hojo, M; Izumi, S; Kamimura, M; Kobayashi, K; Kudo, K; Naka, G; Takeda, Y; Tsuduki, E | 1 |
| Chazouillères, O; Poupon, R; Rosmorduc, O; Serfaty, L; Wendum, D | 1 |
| Charatcharoenwitthaya, P; Lindor, KD | 2 |
| Al-Osaimi, AM; Argo, CK; Caldwell, SH; Chang, CY | 1 |
| Aboutwerat, A; Pemberton, PW; Smith, A; Warnes, TW | 1 |
| Kobayashi, K; Tanaka, N; Yazaki, M | 1 |
| Gossard, AA; Lindor, KD | 1 |
| Poupon, R; Serfaty, L | 1 |
| Bailey, M; Clark, D; Desmond, CP; Roberts, SK; Wilson, J | 1 |
| Boudaya, S; Chaabouni, M; Hachicha, M; Hadj-Taieb, I; Kammon, T; Masmoudi, A; Mseddi, M; Turki, H | 1 |
| Färkkilä, M; Kärkkäinen, P; Karvonen, AL; Niemelä, O; Nurmi, H; Rautiainen, H | 1 |
| Kaplan, MM | 1 |
| Amital, H; Bar-Dayan, Y; Gershwin, ME; Levi, Y; Shoenfeld, Y | 1 |
| Angulo, P; Batts, KP; Dickson, ER; Jorgensen, RA; Lindor, KD; Therneau, TM | 1 |
| Balkau, B; Callard, P; Degott, C; Poupon, R; Poupon, RE; Zafrani, ES | 1 |
| Hansen, BE; Schalm, SW; ten Kate, FJ; van Berge-Henegouwen, GP; van Buuren, HR; van Hoogstraten, HJ | 1 |
| Angulo, P; Batts, KP; Larson, DR; LaRusso, NF; Lindor, KD; Therneau, TM | 1 |
| Harada, H; Kamitsukasa, H; Kojima, H; Murai, S; Tokita, H; Yagura, M | 1 |
| Kumar, KS; Malet, PF | 1 |
| Bonnand, AM; Carrat, F; Corpechot, C; Poupon, R; Poupon, RE | 1 |
| Hahn, EG; Schuppan, D | 1 |
| Kikuchi, S; Kisara, N; Komatsu, K; Maruhama, Y; Shimosegawa, T; Toyota, T; Uchi, M; Ueno, Y | 1 |
| Adachi, Y; Kimura, M; Kobayashi, Y; Koshiyama, H; Makita, Y; Nakao, K; Tanaka, Y; Yoshida, Y | 1 |
| Carrat, F; Corpechot, C; Poupon, R; Poupon, RE | 1 |
60 review(s) available for ursodeoxycholic acid and Disease Exacerbation
| Article | Year |
|---|---|
The Inconvenient Truth of Primary Biliary Cholangitis/Autoimmune Hepatitis Overlap Syndrome.
Topics: Disease Progression; Hepatitis, Autoimmune; Humans; Liver Cirrhosis, Biliary; Syndrome; Ursodeoxycholic Acid | 2022 |
Drug Therapies for Chronic Cholestatic Liver Diseases.
Topics: Animals; Cholagogues and Choleretics; Cholangitis, Sclerosing; Cholestasis; Chronic Disease; Disease Progression; Humans; Liver Cirrhosis, Biliary; Receptors, Cytoplasmic and Nuclear; Ursodeoxycholic Acid | 2020 |
Clinical Management of Primary Biliary Cholangitis-Strategies and Evolving Trends.
Topics: Animals; Bile Acids and Salts; Biomarkers; Chenodeoxycholic Acid; Combined Modality Therapy; Disease Management; Disease Progression; Disease Susceptibility; Fibrosis; Humans; Immunotherapy; Liver Cirrhosis, Biliary; Liver Transplantation; Molecular Targeted Therapy; Severity of Illness Index; Symptom Assessment; Treatment Outcome; Ursodeoxycholic Acid | 2020 |
Current and potential treatments for primary biliary cholangitis.
Topics: Benzothiazoles; Bezafibrate; Bile Acids and Salts; Budesonide; Case-Control Studies; Chenodeoxycholic Acid; Cholagogues and Choleretics; Clinical Trials as Topic; Cyclosporine; Disease Progression; Glucocorticoids; Homeostasis; Humans; Immunologic Factors; Immunosuppressive Agents; Isoxazoles; Liver Cirrhosis, Biliary; Liver Transplantation; Peroxisome Proliferator-Activated Receptors; Receptors, Cytoplasmic and Nuclear; Rituximab; Treatment Outcome; United States; United States Food and Drug Administration; Ursodeoxycholic Acid | 2020 |
Primary biliary cholangitis: pathogenesis and therapeutic opportunities.
Topics: Adaptive Immunity; Animals; Autoimmunity; Bile Acids and Salts; Chenodeoxycholic Acid; Chloride-Bicarbonate Antiporters; Cholagogues and Choleretics; Dihydrolipoyllysine-Residue Acetyltransferase; Disease Progression; Environmental Exposure; Epigenesis, Genetic; Humans; Immunity, Innate; Liver Cirrhosis; Liver Cirrhosis, Biliary; MicroRNAs; Organic Anion Transporters, Sodium-Dependent; Peroxisome Proliferator-Activated Receptors; Receptors, Cytoplasmic and Nuclear; Symporters; Ursodeoxycholic Acid | 2020 |
Emerging therapies for PBC.
Topics: Chenodeoxycholic Acid; Disease Progression; End Stage Liver Disease; Female; Fibric Acids; Humans; Liver Cirrhosis, Biliary; Liver Transplantation; Male; Middle Aged; Ursodeoxycholic Acid | 2020 |
Emerging drugs for the treatment of primary biliary cholangitis.
Topics: Animals; Chenodeoxycholic Acid; Cholagogues and Choleretics; Disease Progression; Drug Development; Humans; Liver Cirrhosis, Biliary; Quality of Life; Ursodeoxycholic Acid | 2020 |
Diagnosis and treatment of primary biliary cholangitis.
Topics: Autoantigens; Autoimmune Diseases; Bezafibrate; Biomarkers; Biopsy; Chenodeoxycholic Acid; Cholagogues and Choleretics; Disease Progression; Drug Therapy, Combination; Elasticity Imaging Techniques; End Stage Liver Disease; Fatigue; Female; Humans; Immunoglobulin M; Liver; Liver Cirrhosis, Biliary; Liver Function Tests; Liver Transplantation; Middle Aged; Off-Label Use; Prognosis; Pruritus; Quality of Life; Severity of Illness Index; Sjogren's Syndrome; Survival Rate; Treatment Outcome; Ursodeoxycholic Acid | 2020 |
Non-alcoholic fatty liver disease and steatohepatitis: State of the art on effective therapeutics based on the gold standard method for diagnosis.
Topics: Biopsy; Disease Progression; Humans; Liver; Liver Cirrhosis; Metformin; Non-alcoholic Fatty Liver Disease; Pentoxifylline; Pioglitazone; Randomized Controlled Trials as Topic; Rosiglitazone; Severity of Illness Index; Treatment Outcome; Ursodeoxycholic Acid; Vitamin E | 2021 |
Treatment of primary sclerosing cholangitis.
Topics: Anti-Bacterial Agents; Bile; Biliary Tract; Cholagogues and Choleretics; Cholangitis, Sclerosing; Disease Progression; Dose-Response Relationship, Drug; Fibric Acids; Gastrointestinal Microbiome; Humans; Immunomodulation; Ursodeoxycholic Acid | 2021 |
What Comes after Ursodeoxycholic Acid in Primary Biliary Cholangitis?
Topics: Chenodeoxycholic Acid; Cholangitis; Disease Progression; Humans; Liver Cirrhosis, Biliary; Quality of Life; Ursodeoxycholic Acid | 2017 |
Primary biliary cholangitis: Old and novel therapy.
Topics: Budesonide; Chenodeoxycholic Acid; Disease Progression; End Stage Liver Disease; Humans; Liver Cirrhosis, Biliary; Liver Transplantation; Randomized Controlled Trials as Topic; Ursodeoxycholic Acid | 2018 |
Investigational drugs in phase II clinical trials for primary biliary cholangitis.
Topics: Animals; Chenodeoxycholic Acid; Cholagogues and Choleretics; Cholangitis; Disease Progression; Drug Design; Drugs, Investigational; Humans; Liver Cirrhosis, Biliary; Ursodeoxycholic Acid | 2017 |
An Update on the Treatment and Follow-up of Patients with Primary Biliary Cholangitis.
Topics: Aftercare; Autoimmune Diseases; Cholagogues and Choleretics; Cholangitis; Disease Management; Disease Progression; Humans; Liver Cirrhosis, Biliary; Liver Transplantation; Ursodeoxycholic Acid | 2017 |
Natural History of Primary Biliary Cholangitis in the Ursodeoxycholic Acid Era: Role of Scoring Systems.
Topics: Bilirubin; Blood Coagulation Disorders; Cholagogues and Choleretics; Disease Progression; End Stage Liver Disease; Humans; Liver Cirrhosis, Biliary; Liver Transplantation; Models, Statistical; Prognosis; Serum Albumin; Time Factors; Treatment Outcome; Ursodeoxycholic Acid | 2018 |
Current Status of Liver Transplantation for Primary Biliary Cholangitis.
Topics: Cholagogues and Choleretics; Disease Progression; End Stage Liver Disease; Graft Survival; Humans; Liver Cirrhosis, Biliary; Liver Transplantation; Recurrence; Ursodeoxycholic Acid | 2018 |
Risk stratification and treatment of primary biliary cholangitis.
Topics: Adult; Age Factors; Alkaline Phosphatase; Biomarkers; Budesonide; Chenodeoxycholic Acid; Cholagogues and Choleretics; Cholangitis; Cholestasis; Disease Progression; Fibric Acids; Glucocorticoids; Humans; Liver Cirrhosis; Liver Transplantation; Middle Aged; Risk Assessment; Risk Factors; Sex Factors; Treatment Failure; Ursodeoxycholic Acid | 2019 |
Primary Biliary Cholangitis and Primary Sclerosing Cholangitis.
Topics: Adult; Biliary Tract; Chenodeoxycholic Acid; Cholagogues and Choleretics; Cholangitis, Sclerosing; Cholestasis; Clinical Trials as Topic; Disease Progression; Drug Therapy, Combination; End Stage Liver Disease; Humans; Immunologic Factors; Life Expectancy; Prevalence; Prognosis; Treatment Outcome; Ursodeoxycholic Acid | 2019 |
The natural history of primary biliary cirrhosis.
Topics: Bile Ducts, Intrahepatic; Cholagogues and Choleretics; Disease Progression; Female; Humans; Liver Cirrhosis, Biliary; Liver Transplantation; Male; Pregnancy; Time Factors; Treatment Outcome; Ursodeoxycholic Acid | 2014 |
Diagnosis and management of overlap syndromes.
Topics: Autoantibodies; Cholagogues and Choleretics; Cholangitis, Sclerosing; Diagnosis, Differential; Disease Progression; Hepatitis, Autoimmune; Humans; Immunoglobulins; Immunosuppressive Agents; Liver Cirrhosis, Biliary; Liver Transplantation; Syndrome; Ursodeoxycholic Acid | 2015 |
Primary biliary cirrhosis: safety and benefits of established and emerging therapies.
Topics: Adult; Animals; Disease Progression; Drug Design; Fatigue; Humans; Liver Cirrhosis, Biliary; Pruritus; Quality of Life; Ursodeoxycholic Acid | 2015 |
Development and Validation of a Scoring System to Predict Outcomes of Patients With Primary Biliary Cirrhosis Receiving Ursodeoxycholic Acid Therapy.
Topics: Adult; Age Factors; Aged; Biomarkers; Cholagogues and Choleretics; Decision Support Techniques; Disease Progression; Disease-Free Survival; Europe; Female; Humans; Kaplan-Meier Estimate; Liver Cirrhosis, Biliary; Liver Transplantation; Male; Middle Aged; Multivariate Analysis; North America; Predictive Value of Tests; Proportional Hazards Models; Reproducibility of Results; Risk Assessment; Risk Factors; Sex Factors; Time Factors; Treatment Outcome; Ursodeoxycholic Acid | 2015 |
A network meta-analysis of the efficacy and side effects of UDCA-based therapies for primary sclerosing cholangitis.
Topics: Adult; Aged; Alkaline Phosphatase; Bilirubin; Cholagogues and Choleretics; Cholangitis, Sclerosing; Disease Progression; Humans; Liver; Liver Transplantation; Metronidazole; Middle Aged; Mycophenolic Acid; Odds Ratio; Proportional Hazards Models; Randomized Controlled Trials as Topic; Research Design; Severity of Illness Index; Treatment Outcome; Ursodeoxycholic Acid; Young Adult | 2015 |
Cell Death and microRNAs in Cholestatic Liver Diseases: Update on Potential Therapeutic Applications.
Topics: Apoptosis; Cholagogues and Choleretics; Cholestasis, Intrahepatic; Disease Progression; Gene Expression Regulation; Genetic Markers; Humans; MicroRNAs; Ursodeoxycholic Acid | 2017 |
Emerging drugs for the treatment of Primary Biliary Cholangitis.
Topics: Alkaline Phosphatase; Animals; Autoantibodies; Cholangitis; Chronic Disease; Disease Progression; Drug Design; Female; Genome-Wide Association Study; Humans; Liver Cirrhosis, Biliary; Male; Mitochondria; Ursodeoxycholic Acid | 2016 |
Toward precision medicine in primary biliary cholangitis.
Topics: Carcinoma, Hepatocellular; Cholagogues and Choleretics; Cholangitis; Clinical Trials as Topic; Disease Progression; Elasticity Imaging Techniques; Humans; Liver Cirrhosis, Biliary; Liver Neoplasms; Precision Medicine; Ursodeoxycholic Acid | 2016 |
Novel therapeutics for primary biliary cholangitis: Toward a disease-stage-based approach.
Topics: Animals; Bile Ducts; Cholagogues and Choleretics; Cholangitis; Disease Progression; End Stage Liver Disease; Humans; Liver Cirrhosis, Biliary; Receptors, Cytoplasmic and Nuclear; Ursodeoxycholic Acid | 2016 |
Insight into the natural history of primary biliary cirrhosis: A systemic review of data from placebo-controlled clinical trials.
Topics: Alkaline Phosphatase; Cholagogues and Choleretics; Disease Progression; Female; Humans; Liver Cirrhosis, Biliary; Male; Middle Aged; Randomized Controlled Trials as Topic; Treatment Outcome; Ursodeoxycholic Acid | 2016 |
Primary Biliary Cholangitis: Medical and Specialty Pharmacy Management Update.
Topics: Chenodeoxycholic Acid; Cholagogues and Choleretics; Cholangitis; Congresses as Topic; Disease Progression; Drug Resistance; Drug Therapy, Combination; Education, Pharmacy, Continuing; End Stage Liver Disease; Evidence-Based Medicine; Formularies as Topic; Humans; Insurance Coverage; Insurance, Pharmaceutical Services; Liver Transplantation; Middle Aged; Prescription Fees; Rare Diseases; Receptors, Cytoplasmic and Nuclear; Satellite Communications; Ursodeoxycholic Acid | 2016 |
Liver fibrosis and hepatic stellate cells: Etiology, pathological hallmarks and therapeutic targets.
Topics: Acetyl-CoA C-Acetyltransferase; Animals; CD4-Positive T-Lymphocytes; Disease Progression; Fatty Liver, Alcoholic; Hepatic Stellate Cells; Humans; Interleukins; Intracellular Signaling Peptides and Proteins; LIM Domain Proteins; Liver Cirrhosis; Macrophages; MicroRNAs; Molecular Targeted Therapy; Non-alcoholic Fatty Liver Disease; Resveratrol; Schistosomiasis; Signal Transduction; Stilbenes; T-Lymphocytes, Regulatory; Triterpenes; Ursodeoxycholic Acid; Ursolic Acid; Virus Diseases | 2016 |
Novel Treatment Strategies for Primary Biliary Cholangitis.
Topics: Chenodeoxycholic Acid; Cholagogues and Choleretics; Cholangitis; Disease Progression; Fibric Acids; Gastrointestinal Agents; Humans; Liver Cirrhosis, Biliary; Randomized Controlled Trials as Topic; Ursodeoxycholic Acid | 2017 |
Clinical features and management of primary biliary cirrhosis.
Topics: Animals; Autoimmune Diseases; Bone Diseases, Metabolic; Cholagogues and Choleretics; Cholestyramine Resin; Disease Progression; Fatigue; Humans; Hyperlipidemias; Hypertension, Portal; Liver Cirrhosis, Biliary; Liver Transplantation; Malnutrition; Pruritus; Risk Factors; Treatment Outcome; Ursodeoxycholic Acid | 2008 |
Clinical features and management of primary sclerosing cholangitis.
Topics: Autoimmune Diseases; Biliary Tract Surgical Procedures; Cholagogues and Choleretics; Cholangitis, Sclerosing; Digestive System Surgical Procedures; Disease Progression; Drug Therapy, Combination; Drugs, Investigational; Endoscopy, Digestive System; Female; Gastrointestinal Agents; Humans; Immunosuppressive Agents; Liver Transplantation; Male; Pregnancy; Pregnancy Complications; Recurrence; Treatment Outcome; Ursodeoxycholic Acid | 2008 |
Update on primary sclerosing cholangitis.
Topics: Autoimmunity; Cholagogues and Choleretics; Cholangiopancreatography, Endoscopic Retrograde; Cholangitis, Sclerosing; Diagnosis, Differential; Diagnostic Imaging; Disease Progression; Genetic Predisposition to Disease; Humans; Immunosuppressive Agents; Liver Transplantation; Practice Guidelines as Topic; Prognosis; Tomography, X-Ray Computed; Ursodeoxycholic Acid | 2010 |
Treatment options for primary sclerosing cholangitis.
Topics: Biliary Tract Surgical Procedures; Cholagogues and Choleretics; Cholangitis, Sclerosing; Dilatation; Disease Progression; Endoscopy, Digestive System; Gastrointestinal Agents; Humans; Liver Transplantation; Time Factors; Treatment Outcome; Ursodeoxycholic Acid | 2010 |
Familial cholestasis: progressive familial intrahepatic cholestasis, benign recurrent intrahepatic cholestasis and intrahepatic cholestasis of pregnancy.
Topics: Adenosine Triphosphatases; ATP Binding Cassette Transporter, Subfamily B; ATP Binding Cassette Transporter, Subfamily B, Member 11; ATP-Binding Cassette Transporters; Bile Acids and Salts; Cholestasis, Intrahepatic; Disease Progression; Female; Humans; Mutation; Pregnancy; Pregnancy Complications; Recurrence; Ursodeoxycholic Acid | 2010 |
Primary biliary cirrhosis.
Topics: Animals; Disease Management; Disease Progression; Environmental Exposure; Humans; Liver; Liver Cirrhosis, Biliary; Liver Transplantation; Major Histocompatibility Complex; Mitochondria, Liver; Treatment Failure; Ursodeoxycholic Acid | 2010 |
Primary sclerosing cholangitis.
Topics: Bile Duct Neoplasms; Bile Ducts, Intrahepatic; Cholangiocarcinoma; Cholangiography; Cholangitis, Sclerosing; Comorbidity; Disease Progression; Gallbladder Neoplasms; Genetic Predisposition to Disease; Genome-Wide Association Study; Humans; Inflammatory Bowel Diseases; Linkage Disequilibrium; Liver Cirrhosis; Liver Transplantation; Practice Guidelines as Topic; Prognosis; Risk Factors; Ursodeoxycholic Acid | 2010 |
Risk factors and prediction of long-term outcome in primary biliary cirrhosis.
Topics: Autoantibodies; Disease Progression; Genetic Predisposition to Disease; HLA-DR Antigens; HLA-DRB1 Chains; Humans; Liver Cirrhosis, Biliary; Liver Failure; Prognosis; Risk Factors; Ursodeoxycholic Acid | 2011 |
[Fatty liver and its clinical management in obese adolescents].
Topics: Adiponectin; Adolescent; Apoptosis; Biomarkers; Chemokines; Disease Progression; Fatty Liver; Fibrosis; Hepatocytes; Humans; Hypertriglyceridemia; Insulin Resistance; Kupffer Cells; Liver Cirrhosis; Liver Transplantation; Metformin; Models, Biological; Non-alcoholic Fatty Liver Disease; Obesity; Oxidative Stress; Ursodeoxycholic Acid; Vitamin E | 2011 |
Systematic review: management options for primary sclerosing cholangitis and its variant forms - IgG4-associated cholangitis and overlap with autoimmune hepatitis.
Topics: Animals; Cholangitis, Sclerosing; Disease Progression; Female; Hepatitis, Autoimmune; Humans; Immunoglobulin G; Immunosuppressive Agents; Male; Mice; Syndrome; Ursodeoxycholic Acid | 2011 |
Progressive familial intrahepatic cholestasis.
Topics: Adenosine Triphosphatases; ATP Binding Cassette Transporter, Subfamily B; ATP Binding Cassette Transporter, Subfamily B, Member 11; ATP-Binding Cassette Transporters; Biomarkers; Cholagogues and Choleretics; Cholestasis; Cholestasis, Intrahepatic; Disease Progression; France; gamma-Glutamyltransferase; Genotype; Humans; Jaundice; Mutation; Prevalence; Prognosis; Pruritus; Treatment Outcome; Ursodeoxycholic Acid | 2012 |
Treatment strategies in autoimmune hepatitis.
Topics: Azathioprine; Budesonide; Clinical Trials as Topic; Cyclosporine; Disease Progression; Hepatitis, Autoimmune; Humans; Immunosuppressive Agents; Mycophenolic Acid; Prednisolone; Tacrolimus; Treatment Outcome; Ursodeoxycholic Acid | 2002 |
[Diseases of the intrahepatic bile duct: diagnosis and principles of treatment].
Topics: Adult; Algorithms; Antibodies, Antineutrophil Cytoplasmic; Bile Duct Diseases; Bile Ducts, Intrahepatic; Biomarkers; Biopsy, Needle; Causality; Child; Cholagogues and Choleretics; Cholangiopancreatography, Endoscopic Retrograde; Decision Trees; Diagnosis, Differential; Disease Progression; Humans; Liver Transplantation; Magnetic Resonance Imaging; Sensitivity and Specificity; Ursodeoxycholic Acid | 2003 |
Combined analysis of the effect of treatment with ursodeoxycholic acid on histologic progression in primary biliary cirrhosis.
Topics: Adult; Aged; Biopsy; Cholagogues and Choleretics; Disease Progression; Female; Humans; Liver Cirrhosis; Liver Cirrhosis, Biliary; Male; Middle Aged; Ursodeoxycholic Acid | 2003 |
Ursodeoxycholic acid for primary biliary cirrhosis: treat early to slow progression.
Topics: Cholagogues and Choleretics; Disease Progression; Humans; Liver Cirrhosis, Biliary; Ursodeoxycholic Acid | 2003 |
[Clinical aspects of type-C cirrhosis of liver--diagnosis, clinical course, treatment and prognosis].
Topics: Antiviral Agents; Carcinoma, Hepatocellular; Cysteine; Disease Progression; Drug Combinations; Drug Therapy, Combination; Fibrosis; Glycine; Hepatitis C, Chronic; Humans; Interferons; Liver; Liver Cirrhosis; Liver Neoplasms; Oleanolic Acid; Prognosis; Ribavirin; Risk; Ursodeoxycholic Acid | 2004 |
Predictive models of natural history in primary biliary cirrhosis.
Topics: Disease Progression; Esophageal and Gastric Varices; Gastrointestinal Hemorrhage; Humans; Liver Cirrhosis, Biliary; Models, Theoretical; Survival Rate; Ursodeoxycholic Acid | 1998 |
Management of primary biliary cirrhosis and autoimmune cholangitis.
Topics: Adrenal Cortex Hormones; Autoimmune Diseases; Cholangitis; Colchicine; Disease Progression; Drug Therapy, Combination; Humans; Liver Cirrhosis, Biliary; Penicillamine; Ursodeoxycholic Acid | 1998 |
Long-term ursodeoxycholic acid therapy for primary biliary cirrhosis: a follow-up to 12 years.
Topics: Adult; Aged; Alkaline Phosphatase; Bilirubin; Cholagogues and Choleretics; Disease Progression; Female; Follow-Up Studies; Humans; Liver Cirrhosis, Biliary; Liver Transplantation; Male; Middle Aged; Statistics, Nonparametric; Treatment Outcome; Ursodeoxycholic Acid | 2005 |
Ursodeoxycholic acid in the therapy for primary biliary cirrhosis: effects on progression and prognosis.
Topics: Disease Progression; Humans; Liver Cirrhosis, Biliary; Prognosis; Recovery of Function; Risk Assessment; Risk Factors; Survival Analysis; Survival Rate; Treatment Outcome; Ursodeoxycholic Acid | 2005 |
Overlap syndromes.
Topics: Adult; Age of Onset; Aged; Cholagogues and Choleretics; Cholangitis, Sclerosing; Comorbidity; Diagnosis, Differential; Disease Progression; Female; Hepatitis, Autoimmune; Humans; Immunosuppressive Agents; Liver Cirrhosis, Biliary; Liver Failure; Male; Prognosis; Syndrome; Ursodeoxycholic Acid | 2005 |
Future Treatment Options in PBC.
Topics: Autoimmunity; Cell Movement; Cell Proliferation; Cholagogues and Choleretics; Combined Modality Therapy; Disease Progression; Enzyme Inhibitors; Humans; Immunoglobulins; Immunotherapy; Inflammation; Liver Cirrhosis; Liver Cirrhosis, Biliary; Oxidation-Reduction; T-Lymphocytes; Ursodeoxycholic Acid | 2005 |
Primary sclerosing cholangitis: diagnosis and management.
Topics: Autoimmune Diseases; Cholagogues and Choleretics; Cholangiography; Cholangitis, Sclerosing; Colitis, Ulcerative; Disease Progression; Drug Therapy, Combination; Female; Humans; Immunosuppressive Agents; Liver Transplantation; Lymphocytes; Male; Prognosis; Recurrence; Ursodeoxycholic Acid | 2006 |
Therapy of NAFLD: antioxidants and cytoprotective agents.
Topics: Acetylcysteine; Antioxidants; Betaine; Cholagogues and Choleretics; Disease Progression; Fatty Liver; Humans; Lipid Peroxidation; S-Adenosylmethionine; Ursodeoxycholic Acid; Vitamin E | 2006 |
Ursodeoxycholic acid in chronic hepatitis C.
Topics: Apoptosis; Cholagogues and Choleretics; Disease Progression; Hepatitis C, Chronic; Humans; Liver Neoplasms; Ursodeoxycholic Acid | 2007 |
The use of methotrexate, colchicine, and other immunomodulatory drugs in the treatment of primary biliary cirrhosis.
Topics: Adjuvants, Immunologic; Cholagogues and Choleretics; Colchicine; Disease Progression; Drug Therapy, Combination; Female; Gout Suppressants; Humans; Immunosuppressive Agents; Liver Cirrhosis, Biliary; Male; Methotrexate; Ursodeoxycholic Acid | 1997 |
Primary biliary cirrhosis. Is (and how much of) the pathology preventible?
Topics: Antibodies; Antibody Specificity; Autoimmune Diseases; Biomarkers; Cholagogues and Choleretics; Chronic Disease; Disease Progression; Humans; Liver Cirrhosis, Biliary; Mitochondria; Risk Factors; Ursodeoxycholic Acid | 1998 |
Progressive familial intrahepatic cholestasis.
Topics: Adenosine Triphosphatases; Adolescent; ATP Binding Cassette Transporter, Subfamily B; ATP Binding Cassette Transporter, Subfamily B, Member 11; ATP-Binding Cassette Transporters; Child, Preschool; Cholagogues and Choleretics; Cholestasis, Intrahepatic; Disease Progression; gamma-Glutamyltransferase; Humans; Infant; Infant, Newborn; Liver Transplantation; Ursodeoxycholic Acid | 1999 |
Nonalcoholic steatohepatitis.
Topics: Age Factors; Biopsy; Child; Cholagogues and Choleretics; Diabetes Complications; Disease Progression; Fatty Liver; Hepatitis; Humans; Hyperlipidemias; Hypertension, Portal; Liver Cirrhosis; Middle Aged; Obesity; Ursodeoxycholic Acid | 2000 |
13 trial(s) available for ursodeoxycholic acid and Disease Exacerbation
| Article | Year |
|---|---|
A randomized controlled trial comparing the effects of Vitamin E, Ursodeoxycholic acid and Pentoxifylline on Egyptian non-alcoholic steatohepatitis patients.
Topics: Adult; Antioxidants; Cholagogues and Choleretics; Disease Progression; Egypt; Female; Humans; Male; Middle Aged; Non-alcoholic Fatty Liver Disease; Oxidative Stress; Pentoxifylline; Phosphodiesterase Inhibitors; Prospective Studies; Single-Blind Method; Treatment Outcome; Ursodeoxycholic Acid; Vitamin E | 2021 |
A phase II, randomized, open-label, 52-week study of seladelpar in patients with primary biliary cholangitis.
Topics: Acetates; Adult; Alkaline Phosphatase; Disease Progression; Humans; Liver Cirrhosis, Biliary; Pruritus; Ursodeoxycholic Acid | 2022 |
Ursodeoxycholic acid as a novel disease-modifying treatment for Parkinson's disease: protocol for a two-centre, randomised, double-blind, placebo-controlled trial, The 'UP' study.
Topics: Disease Progression; Double-Blind Method; England; Humans; Parkinson Disease; Randomized Controlled Trials as Topic; Treatment Outcome; Ursodeoxycholic Acid | 2020 |
A placebo-controlled randomised trial of budesonide for PBC following an insufficient response to UDCA.
Topics: Alkaline Phosphatase; Anti-Inflammatory Agents; Biopsy; Budesonide; Cholagogues and Choleretics; Disease Progression; Double-Blind Method; Drug Monitoring; Female; Humans; Liver; Liver Cirrhosis; Liver Cirrhosis, Biliary; Liver Function Tests; Male; Middle Aged; Treatment Outcome; Ursodeoxycholic Acid | 2021 |
Ursodeoxycholic Acid at 18-22 mg/kg/d Showed a Promising Capacity for Treating Refractory Primary Biliary Cholangitis.
Topics: Cholagogues and Choleretics; Cholangitis; Disease Progression; Humans; Liver Cirrhosis, Biliary; Treatment Outcome; Ursodeoxycholic Acid | 2021 |
Combined analysis of the effect of treatment with ursodeoxycholic acid on histologic progression in primary biliary cirrhosis.
Topics: Adult; Aged; Biopsy; Cholagogues and Choleretics; Disease Progression; Female; Humans; Liver Cirrhosis; Liver Cirrhosis, Biliary; Male; Middle Aged; Ursodeoxycholic Acid | 2003 |
Ursodeoxycholic acid for treatment of nonalcoholic steatohepatitis: results of a randomized trial.
Topics: Alanine Transaminase; Aspartate Aminotransferases; Cholagogues and Choleretics; Disease Progression; Double-Blind Method; Fatty Liver; Fibrosis; Humans; Liver; Necrosis; Ursodeoxycholic Acid | 2004 |
A phase I/II trial of irinotecan-cisplatin combined with an anti-late-diarrhoeal programme to evaluate the safety and antitumour response of this combination therapy in patients with advanced non-small-cell lung cancer.
Topics: Administration, Oral; Adult; Aged; Antacids; Antidiarrheals; Antineoplastic Combined Chemotherapy Protocols; Area Under Curve; Camptothecin; Carcinoma, Non-Small-Cell Lung; Cholagogues and Choleretics; Cisplatin; Diarrhea; Disease Progression; Female; Humans; Infusions, Intravenous; Irinotecan; Lung Neoplasms; Magnesium Oxide; Male; Maximum Tolerated Dose; Middle Aged; Sodium Bicarbonate; Survival Analysis; Ursodeoxycholic Acid | 2005 |
The benign course of liver disease in adults with cystic fibrosis and the effect of ursodeoxycholic acid.
Topics: Adolescent; Adult; Child; Cholagogues and Choleretics; Cystic Fibrosis; Disease Progression; Female; Follow-Up Studies; Humans; Hypertension, Portal; Liver Diseases; Liver Function Tests; Male; Middle Aged; Severity of Illness Index; Treatment Outcome; Ursodeoxycholic Acid | 2007 |
Serological markers for monitoring disease progression in noncirrhotic primary biliary cirrhosis on ursodeoxycholic acid therapy.
Topics: Anti-Inflammatory Agents; Aspartate Aminotransferases; Bile Acids and Salts; Biomarkers; Biopsy; Budesonide; Cholagogues and Choleretics; Disease Progression; Drug Therapy, Combination; Fibrosis; Humans; Hyaluronic Acid; Liver; Liver Cirrhosis, Biliary; Liver Function Tests; Peptide Fragments; Predictive Value of Tests; Procollagen; Prospective Studies; ROC Curve; Ursodeoxycholic Acid | 2008 |
Long-term ursodeoxycholic acid delays histological progression in primary biliary cirrhosis.
Topics: Adult; Aged; Cholagogues and Choleretics; Disease Progression; Female; Humans; Liver Cirrhosis; Liver Cirrhosis, Biliary; Middle Aged; Penicillamine; Time Factors; Treatment Outcome; Ursodeoxycholic Acid | 1999 |
Histopathological study of primary biliary cirrhosis and the effect of ursodeoxycholic acid treatment on histology progression.
Topics: Bile Ducts; Biopsy; Cholagogues and Choleretics; Cohort Studies; Disease Progression; Double-Blind Method; Humans; Liver Cirrhosis, Biliary; Prognosis; Treatment Outcome; Ursodeoxycholic Acid | 1999 |
The effect of ursodeoxycholic acid therapy on liver fibrosis progression in primary biliary cirrhosis.
Topics: Disease Progression; Double-Blind Method; Humans; Liver Cirrhosis; Liver Cirrhosis, Biliary; Markov Chains; Randomized Controlled Trials as Topic; Ursodeoxycholic Acid | 2000 |
72 other study(ies) available for ursodeoxycholic acid and Disease Exacerbation
| Article | Year |
|---|---|
Review of Medical Management of Primary Biliary Cholangitis.
Topics: Cholagogues and Choleretics; Cholestasis; Disease Progression; Humans; Liver Cirrhosis, Biliary; Ursodeoxycholic Acid | 2021 |
Value of controlled attenuation parameter in fibrosis prediction in nonalcoholic steatohepatitis.
Topics: Adult; Biopsy; Disease Progression; Elasticity Imaging Techniques; Female; Follow-Up Studies; Humans; Liver; Liver Cirrhosis; Male; Middle Aged; Non-alcoholic Fatty Liver Disease; Pioglitazone; Predictive Value of Tests; Prognosis; Retrospective Studies; ROC Curve; Ursodeoxycholic Acid | 2019 |
Fibrosis stage is an independent predictor of outcome in primary biliary cholangitis despite biochemical treatment response.
Topics: Adult; Biomarkers, Pharmacological; Biopsy; Cohort Studies; Disease Progression; Female; Humans; Liver; Liver Cirrhosis; Liver Cirrhosis, Biliary; Liver Function Tests; Male; Middle Aged; Predictive Value of Tests; Prognosis; Severity of Illness Index; Treatment Outcome; Ursodeoxycholic Acid | 2019 |
Concomitant systemic lupus erythematosus might have a negative impact on the biochemical responses to treatment in patients with primary biliary cholangitis.
Topics: Adult; Aged; Alkaline Phosphatase; Bilirubin; China; Disease Progression; Female; Humans; Kaplan-Meier Estimate; Liver Cirrhosis, Biliary; Lupus Erythematosus, Systemic; Male; Middle Aged; Prognosis; Retrospective Studies; Ursodeoxycholic Acid; Young Adult | 2020 |
Novel Anti-Hexokinase 1 Antibodies Are Associated With Poor Prognosis in Patients With Primary Biliary Cholangitis.
Topics: Adaptor Proteins, Signal Transducing; Adult; Antigens, Nuclear; Autoantibodies; Autoantigens; Cholagogues and Choleretics; Disease Progression; Female; Hexokinase; Humans; Immunosuppressive Agents; Liver Cirrhosis, Biliary; Liver Transplantation; Male; Middle Aged; Mitochondrial Proteins; Nuclear Pore Complex Proteins; Prognosis; Ursodeoxycholic Acid | 2020 |
A nomogram based on pretreatment clinical parameters for the prediction of inadequate biochemical response in primary biliary cholangitis.
Topics: Adult; Disease Progression; Female; Humans; Liver Cirrhosis, Biliary; Male; Middle Aged; Nomograms; Predictive Value of Tests; Prognosis; Risk Factors; Treatment Outcome; Ursodeoxycholic Acid | 2020 |
Glycoursodeoxycholic Acid Ameliorates Atherosclerosis and Alters Gut Microbiota in Apolipoprotein E-Deficient Mice.
Topics: Animals; Apolipoproteins E; Atherosclerosis; Cells, Cultured; Disease Models, Animal; Disease Progression; Down-Regulation; Female; Foam Cells; Gastrointestinal Microbiome; Gene Expression Regulation; Humans; Immunohistochemistry; Male; Mice; Mice, Inbred C57BL; Mice, Knockout; RNA, Messenger; Scavenger Receptors, Class A; Ursodeoxycholic Acid | 2021 |
Predictors for incomplete response to ursodeoxycholic acid in primary biliary cholangitis. Data from a national registry of liver disease.
Topics: Adult; Aged; Alkaline Phosphatase; Disease Progression; Female; gamma-Glutamyltransferase; Humans; Liver Cirrhosis, Biliary; Logistic Models; Male; Middle Aged; Multivariate Analysis; Portugal; Predictive Value of Tests; Registries; Risk Factors; Severity of Illness Index; Treatment Failure; Ursodeoxycholic Acid | 2021 |
Finding the cure for primary biliary cholangitis - Still waiting.
Topics: Biomarkers; Chenodeoxycholic Acid; Cholagogues and Choleretics; Disease Progression; Humans; Liver Cirrhosis, Biliary; Ursodeoxycholic Acid | 2017 |
Primary Biliary Cholangitis: advances in management and treatment of the disease.
Topics: Chenodeoxycholic Acid; Cholagogues and Choleretics; Cholangitis; Cholestasis; Disease Progression; Drug Therapy, Combination; End Stage Liver Disease; Humans; Ursodeoxycholic Acid | 2017 |
Effects of Bezafibrate on Outcome and Pruritus in Primary Biliary Cholangitis With Suboptimal Ursodeoxycholic Acid Response.
Topics: Alkaline Phosphatase; Bezafibrate; Carcinoma, Hepatocellular; Cholagogues and Choleretics; Disease Progression; Drug Therapy, Combination; Elasticity Imaging Techniques; Female; Humans; Hypolipidemic Agents; Jaundice; Liver Cirrhosis, Biliary; Liver Neoplasms; Liver Transplantation; Male; Middle Aged; Prognosis; Pruritus; Ursodeoxycholic Acid; Visual Analog Scale | 2018 |
Major Hepatic Complications in Ursodeoxycholic Acid-Treated Patients With Primary Biliary Cholangitis: Risk Factors and Time Trends in Incidence and Outcome.
Topics: Adult; Aged; Ascites; Aspartate Aminotransferases; Cholagogues and Choleretics; Cohort Studies; Disease Progression; Esophageal and Gastric Varices; Europe; Female; Gastrointestinal Hemorrhage; Hepatic Encephalopathy; Humans; Incidence; Kaplan-Meier Estimate; Liver Cirrhosis, Biliary; Male; Middle Aged; North America; Platelet Count; Population Growth; Prognosis; Proportional Hazards Models; Risk Factors; Ursodeoxycholic Acid | 2018 |
The British Society of Gastroenterology/UK-PBC primary biliary cholangitis treatment and management guidelines.
Topics: Alanine Transaminase; Alkaline Phosphatase; Autoantibodies; Bilirubin; Biomarkers; Chenodeoxycholic Acid; Cholagogues and Choleretics; Cholangitis; Disease Progression; Gastroenterology; Humans; Liver Cirrhosis, Biliary; Mitochondria; Predictive Value of Tests; Risk Assessment; Risk Factors; Sensitivity and Specificity; Societies, Medical; Treatment Outcome; United Kingdom; Ursodeoxycholic Acid | 2018 |
Are Clinicians Ready for Safe Use of Stratified Therapy in Primary Biliary Cholangitis (PBC)? A Study of Educational Awareness.
Topics: Chenodeoxycholic Acid; Cholagogues and Choleretics; Clinical Competence; Disease Progression; Early Diagnosis; Gastroenterologists; Humans; Liver Cirrhosis, Biliary; Risk Factors; Ursodeoxycholic Acid | 2018 |
Autoimmune hepatitis - primary biliary cholangitis overlap syndrome. Long-term outcomes of a retrospective cohort in a university hospital.
Topics: Adrenal Cortex Hormones; Adult; Colombia; Disease Progression; Female; Follow-Up Studies; Hepatitis, Autoimmune; Hospitals, University; Humans; Immunosuppressive Agents; Liver Cirrhosis, Biliary; Liver Transplantation; Male; Middle Aged; Retrospective Studies; Syndrome; Ursodeoxycholic Acid | 2018 |
Primary biliary cholangitis : therapeutic and evolving aspects about 46 cases.
Topics: Adrenal Cortex Hormones; Adult; Aged; Aged, 80 and over; Diagnosis, Differential; Disease Progression; Drug Therapy, Combination; Female; Hepatitis, Autoimmune; Humans; Immunosuppressive Agents; Liver Cirrhosis; Liver Cirrhosis, Biliary; Liver Transplantation; Male; Middle Aged; Prevalence; Retrospective Studies; Syndrome; Treatment Outcome; Ursodeoxycholic Acid; Young Adult | 2018 |
Pruritus Is Common and Undertreated in Patients With Primary Biliary Cholangitis in the United Kingdom.
Topics: Cholagogues and Choleretics; Cholangitis; Cross-Sectional Studies; Disease Progression; Female; Follow-Up Studies; Humans; Male; Middle Aged; Prevalence; Prognosis; Pruritus; Retrospective Studies; Risk Assessment; Severity of Illness Index; Surveys and Questionnaires; United Kingdom; Ursodeoxycholic Acid | 2019 |
Δ4-3-oxosteroid-5β-reductase deficiency: Responses to oral bile acid therapy and long-term outcomes.
Topics: Administration, Oral; Chenodeoxycholic Acid; Disease Progression; DNA Mutational Analysis; Dose-Response Relationship, Drug; Female; Gastrointestinal Agents; Humans; Infant, Newborn; Male; Metabolic Diseases; Mutation; Oxidoreductases; Retrospective Studies; Treatment Outcome; Ursodeoxycholic Acid | 2019 |
Cholestasis affects enteral tolerance and prospective weight gain in the NICU.
Topics: Bilirubin; Birth Weight; Cholagogues and Choleretics; Cholestasis; Digestive System Surgical Procedures; Disease Progression; Fat Emulsions, Intravenous; Female; Fibrosis; Fish Oils; Humans; Hyperbilirubinemia; Infant; Infant Nutritional Physiological Phenomena; Infant, Newborn; Infant, Premature; Intensive Care Units, Neonatal; Male; Parenteral Nutrition; Postoperative Complications; Prognosis; Retrospective Studies; Ursodeoxycholic Acid; Weight Gain | 2019 |
Ursodeoxycholic acid therapy and liver transplant-free survival in patients with primary biliary cholangitis.
Topics: Adult; Aged; Cholagogues and Choleretics; Cholangitis; Disease Progression; Female; Follow-Up Studies; Humans; Liver Cirrhosis, Biliary; Liver Transplantation; Male; Middle Aged; Proportional Hazards Models; Risk; Survival Rate; Treatment Outcome; Ursodeoxycholic Acid | 2019 |
Pediatric-onset primary biliary cholangitis.
Topics: Adolescent; Age of Onset; Cholagogues and Choleretics; Disease Progression; Humans; Liver; Liver Cirrhosis, Biliary; Liver Transplantation; Male; Ursodeoxycholic Acid | 2019 |
Validation of Risk Scoring Systems in Ursodeoxycholic Acid-Treated Patients With Primary Biliary Cholangitis.
Topics: Adult; Age Factors; Cholagogues and Choleretics; Cohort Studies; Disease Progression; Dose-Response Relationship, Drug; Drug Administration Schedule; Female; Humans; Internationality; Kaplan-Meier Estimate; Liver Cirrhosis, Biliary; Male; Middle Aged; Predictive Value of Tests; Prognosis; Proportional Hazards Models; Retrospective Studies; Risk Assessment; Severity of Illness Index; Sex Factors; Survival Analysis; Treatment Outcome; Ursodeoxycholic Acid | 2019 |
Concomitant Sjögren's Syndrome Was Not Associated with a Poorer Response or Outcomes in Ursodeoxycholic Acid-Treated Patients with Primary Biliary Cholangitis.
Topics: Adult; China; Cholagogues and Choleretics; Disease Progression; Female; Humans; Liver Cirrhosis, Biliary; Liver Function Tests; Male; Middle Aged; Retrospective Studies; Sjogren's Syndrome; Treatment Outcome; Ursodeoxycholic Acid | 2019 |
Risk factors for hepatic decompensation in patients with primary biliary cirrhosis.
Topics: Adult; Biomarkers; Chi-Square Distribution; China; Cholagogues and Choleretics; Disease Progression; Female; Humans; Kaplan-Meier Estimate; Liver Cirrhosis, Biliary; Liver Failure; Liver Transplantation; Male; Middle Aged; Proportional Hazards Models; Prospective Studies; Risk Factors; Time Factors; Treatment Outcome; Ursodeoxycholic Acid | 2013 |
Sequential presentation of primary biliary cirrhosis and autoimmune hepatitis.
Topics: Adolescent; Adult; Aged; Biomarkers; Disease Progression; Drug Therapy, Combination; Europe; Female; Gastrointestinal Agents; Hepatitis, Autoimmune; Humans; Immunosuppressive Agents; Liver; Liver Cirrhosis, Biliary; Liver Transplantation; Male; Middle Aged; Remission Induction; Retrospective Studies; Risk Factors; Syndrome; Time Factors; Treatment Outcome; United States; Ursodeoxycholic Acid; Young Adult | 2014 |
Fatigue and pruritus at onset identify a more aggressive subset of primary biliary cirrhosis.
Topics: Adult; Alkaline Phosphatase; Autoantibodies; Blotting, Western; Cohort Studies; Disease Progression; Enzyme-Linked Immunosorbent Assay; Fatigue; Female; Fluorescent Antibody Technique, Indirect; Follow-Up Studies; Humans; Italy; Kaplan-Meier Estimate; Liver Cirrhosis, Biliary; Male; Middle Aged; Pruritus; Transaminases; Ursodeoxycholic Acid | 2015 |
Long-term outcome in PSC/AIH "overlap syndrome": does immunosuppression also treat the PSC component?
Topics: Adult; Cholangitis, Sclerosing; Disease Progression; Follow-Up Studies; Hepatitis, Autoimmune; Humans; Immunosuppression Therapy; Liver Transplantation; Male; Middle Aged; Syndrome; Treatment Outcome; Ursodeoxycholic Acid | 2014 |
Canals of Hering loss relates to the progression of the histological stages of primary biliary cirrhosis.
Topics: Aged; Alkaline Phosphatase; Bile Ducts, Intrahepatic; Bilirubin; Biomarkers; Biopsy; Case-Control Studies; Disease Progression; Female; Humans; Immunohistochemistry; Liver; Liver Cirrhosis, Biliary; Male; Middle Aged; Predictive Value of Tests; Severity of Illness Index; Stem Cells; Time Factors; Treatment Outcome; Ursodeoxycholic Acid | 2015 |
Serum Wisteria floribunda Agglutinin-Positive Mac-2-Binding Protein Level Predicts Liver Fibrosis and Prognosis in Primary Biliary Cirrhosis.
Topics: Antigens, Neoplasm; Case-Control Studies; Cholagogues and Choleretics; Cohort Studies; Disease Progression; Female; Humans; Liver Cirrhosis; Liver Cirrhosis, Biliary; Male; Membrane Glycoproteins; Middle Aged; Plant Lectins; Prognosis; Proportional Hazards Models; Receptors, N-Acetylglucosamine; Retrospective Studies; Ursodeoxycholic Acid | 2015 |
Alkaline phosphatase at diagnosis of primary sclerosing cholangitis and 1 year later: evaluation of prognostic value.
Topics: Adult; Alkaline Phosphatase; Biomarkers; Cholangitis, Sclerosing; Disease Progression; Female; Humans; Longitudinal Studies; Male; Middle Aged; Netherlands; Prognosis; Retrospective Studies; Ursodeoxycholic Acid; Young Adult | 2016 |
Looking Into the Crystal Ball: Predicting Non-response to Ursodeoxycholic Acid in Primary Biliary Cholangitis.
Topics: Cholagogues and Choleretics; Cholangitis, Sclerosing; Disease Progression; Humans; Prognosis; Treatment Outcome; Ursodeoxycholic Acid | 2017 |
Portal hypertension and primary biliary cirrhosis: effect of long-term ursodeoxycholic acid treatment.
Topics: Adult; Aged; Aspartate Aminotransferases; Cholagogues and Choleretics; Confidence Intervals; Disease Progression; Female; Follow-Up Studies; Humans; Hypertension, Portal; Liver Cirrhosis, Biliary; Male; Middle Aged; Odds Ratio; Portal Pressure; Prevalence; Prognosis; Quebec; Retrospective Studies; Survival Rate; Time Factors; Treatment Outcome; Ursodeoxycholic Acid | 2008 |
Characteristics and long-term prognosis of the autoimmune hepatitis/primary sclerosing cholangitis overlap syndrome.
Topics: Adolescent; Adult; Aged; Cholangiography; Cholangitis, Sclerosing; Disease Progression; Drug Therapy, Combination; Female; Fibrosis; Follow-Up Studies; Hepatitis, Autoimmune; Humans; Immunosuppressive Agents; Liver Cirrhosis; Male; Middle Aged; Prognosis; Retrospective Studies; Syndrome; Ursodeoxycholic Acid; Young Adult | 2009 |
Analysis of colorectal adenoma recurrence data subject to informative censoring.
Topics: Adenoma; Cholagogues and Choleretics; Colonic Polyps; Colorectal Neoplasms; Disease Progression; Humans; Kaplan-Meier Estimate; Models, Statistical; Neoplasm Recurrence, Local; Prognosis; Ursodeoxycholic Acid | 2009 |
Early biochemical response to ursodeoxycholic acid predicts symptom development in patients with asymptomatic primary biliary cirrhosis.
Topics: Adult; Aged; Aged, 80 and over; Cholagogues and Choleretics; Disease Progression; Female; Humans; Liver; Liver Cirrhosis, Biliary; Male; Middle Aged; Multivariate Analysis; Prognosis; Proportional Hazards Models; Retrospective Studies; Treatment Outcome; Ursodeoxycholic Acid | 2009 |
Overlap of primary biliary cirrhosis and autoimmune hepatitis: Characteristics, therapy, and long term outcomes.
Topics: Alanine Transaminase; Alkaline Phosphatase; Biomarkers; Diagnosis, Differential; Disease Progression; Drug Therapy, Combination; Female; Hepatitis, Autoimmune; Humans; Immunosuppressive Agents; Liver Cirrhosis, Biliary; Male; Middle Aged; Predictive Value of Tests; Prednisolone; Retrospective Studies; Time Factors; Treatment Outcome; Ursodeoxycholic Acid | 2010 |
Bile acid profiles in intrahepatic cholestasis of pregnancy: is this the solution to the enigma of intrahepatic cholestasis of pregnancy?
Topics: Adult; Bile Acids and Salts; Cholestasis, Intrahepatic; Chromatography; Disease Progression; Female; Humans; Liver Function Tests; Pregnancy; Pregnancy Complications; Pruritus; Risk Factors; Time Factors; Ursodeoxycholic Acid | 2010 |
Titration of bile acid supplements in 3beta-hydroxy-Delta 5-C27-steroid dehydrogenase/isomerase deficiency.
Topics: 3-Hydroxysteroid Dehydrogenases; Biopsy; Chenodeoxycholic Acid; Child; Child, Preschool; Cholagogues and Choleretics; Cholic Acids; Chromatography, Liquid; Dietary Supplements; Disease Progression; Humans; Infant; Infant, Newborn; Isomerases; Liver Diseases; Steroid Metabolism, Inborn Errors; Tandem Mass Spectrometry; Treatment Outcome; Ursodeoxycholic Acid | 2010 |
Baseline ductopenia and treatment response predict long-term histological progression in primary biliary cirrhosis.
Topics: Adult; Alkaline Phosphatase; Disease Progression; Female; Humans; Immunoglobulins; Liver; Liver Cirrhosis, Biliary; Male; Middle Aged; Odds Ratio; Patient Selection; Predictive Value of Tests; Regression Analysis; Retrospective Studies; Treatment Outcome; Ursodeoxycholic Acid | 2010 |
Methotrexate in patients with primary biliary cirrhosis who respond incompletely to treatment with ursodeoxycholic acid.
Topics: Alkaline Phosphatase; Aspartate Aminotransferases; Bilirubin; Cholagogues and Choleretics; Colchicine; Disease Progression; Drug Therapy, Combination; Fibrosis; Humans; Immunosuppressive Agents; Liver; Liver Cirrhosis, Biliary; Liver Function Tests; Methotrexate; Treatment Failure; Ursodeoxycholic Acid | 2010 |
Bile acid changes after high-dose ursodeoxycholic acid treatment in primary sclerosing cholangitis: Relation to disease progression.
Topics: Adolescent; Adult; Aged; Bile Acids and Salts; Cholagogues and Choleretics; Cholangitis, Sclerosing; Disease Progression; Dose-Response Relationship, Drug; Double-Blind Method; Female; Humans; Lithocholic Acid; Male; Middle Aged; Randomized Controlled Trials as Topic; Treatment Outcome; Ursodeoxycholic Acid; Young Adult | 2010 |
A 35-year follow-up of a large cohort of patients with primary biliary cirrhosis seen at a single centre.
Topics: Cause of Death; Cholagogues and Choleretics; Disease Progression; Female; Follow-Up Studies; Humans; Italy; Liver Cirrhosis, Biliary; Liver Failure; Male; Middle Aged; Prognosis; Prospective Studies; Survival Rate; Treatment Outcome; Ursodeoxycholic Acid | 2011 |
[A two-year follow-up study on the efficacy of ursodeoxycholic acid on primary biliary cirrhosis in different stages].
Topics: Adult; Disease Progression; Female; Follow-Up Studies; Humans; Liver Cirrhosis, Biliary; Male; Middle Aged; Treatment Outcome; Ursodeoxycholic Acid | 2010 |
Nor-ursodeoxycholic acid reverses hepatocyte-specific nemo-dependent steatohepatitis.
Topics: Animals; Anti-Inflammatory Agents, Non-Steroidal; Apoptosis; Cell Proliferation; Diet, Fat-Restricted; Disease Progression; Down-Regulation; Drug Evaluation, Preclinical; Fatty Liver; Hepatocytes; Intracellular Signaling Peptides and Proteins; Lipids; Liver; Liver Cirrhosis; Mice; Mice, Knockout; Oligonucleotide Array Sequence Analysis; Ursodeoxycholic Acid | 2011 |
Clinical features and genotype-phenotype correlations in children with progressive familial intrahepatic cholestasis type 3 related to ABCB4 mutations.
Topics: Adolescent; Alleles; Child; Child, Preschool; Cholestasis, Intrahepatic; Codon, Nonsense; Disease Progression; Exons; Female; Frameshift Mutation; gamma-Glutamyltransferase; Genotype; Humans; Infant; Italy; Liver Cirrhosis; Male; Phenotype; Polymorphism, Single Nucleotide; Severity of Illness Index; Statistics, Nonparametric; Treatment Outcome; Ursodeoxycholic Acid | 2011 |
Discriminant analysis using a multivariate linear mixed model with a normal mixture in the random effects distribution.
Topics: Biomarkers; Cholagogues and Choleretics; Computer Simulation; Data Interpretation, Statistical; Discriminant Analysis; Disease Progression; Humans; Linear Models; Liver Cirrhosis, Biliary; Longitudinal Studies; Ursodeoxycholic Acid | 2010 |
Novel developments in IBD-related sclerosing cholangitis.
Topics: Animals; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Cholagogues and Choleretics; Cholangitis, Sclerosing; Disease Progression; Humans; Immunosuppressive Agents; Inflammatory Bowel Diseases; Natalizumab; Ursodeoxycholic Acid | 2011 |
In PSC with colitis treated with UDCA, most colonic carcinomas develop in the first years after the start of treatment.
Topics: Adolescent; Adult; Aged; Child; Cholagogues and Choleretics; Cholangiopancreatography, Endoscopic Retrograde; Cholangitis, Sclerosing; Colonoscopy; Colorectal Neoplasms; Disease Progression; Dose-Response Relationship, Drug; Female; Follow-Up Studies; Germany; Humans; Male; Middle Aged; Neoplasm Staging; Prospective Studies; Risk Factors; Time Factors; Ursodeoxycholic Acid; Young Adult | 2011 |
Alterations in lipid metabolism mediate inflammation, fibrosis, and proliferation in a mouse model of chronic cholestatic liver injury.
Topics: Animals; ATP Binding Cassette Transporter, Subfamily B; ATP-Binding Cassette Sub-Family B Member 4; Bile Acids and Salts; Cell Proliferation; Cholestasis, Intrahepatic; Chronic Disease; Dietary Fats; Disease Models, Animal; Disease Progression; Fatty Acids; Female; Fenofibrate; Gene Expression Profiling; Gene Expression Regulation; Hepatitis; Hypolipidemic Agents; Lipid Metabolism; Liver; Liver Cirrhosis; Metabolomics; Mice; Mice, Knockout; Oligonucleotide Array Sequence Analysis; PPAR gamma; Pregnancy; Prenatal Exposure Delayed Effects; Triglycerides; Ursodeoxycholic Acid | 2012 |
Optimizing biochemical markers as endpoints for clinical trials in primary biliary cirrhosis.
Topics: Alkaline Phosphatase; Ascites; Bilirubin; Biomarkers; Cholagogues and Choleretics; Clinical Trials as Topic; Disease Progression; Endpoint Determination; Female; Hepatic Encephalopathy; Humans; Liver Cirrhosis, Biliary; Liver Transplantation; Male; Middle Aged; Multicenter Studies as Topic; Retrospective Studies; Treatment Outcome; Ursodeoxycholic Acid; Varicose Veins | 2012 |
Primary sclerosing cholangitis and bile acids.
Topics: Age Distribution; Bile Acids and Salts; Cholagogues and Choleretics; Cholangitis, Sclerosing; Disease Progression; France; Humans; Prevalence; Prognosis; Randomized Controlled Trials as Topic; Risk Assessment; Risk Factors; Treatment Outcome; Ursodeoxycholic Acid | 2012 |
[A clinical study of bilirubin rise in short-term in patients with primary biliary cirrhosis].
Topics: Adult; Bilirubin; Biomarkers; Disease Progression; Drugs, Chinese Herbal; Female; Humans; Liver; Liver Cirrhosis, Biliary; Liver Function Tests; Male; Middle Aged; S-Adenosylmethionine; Ursodeoxycholic Acid | 2012 |
Survival and symptom progression in a geographically based cohort of patients with primary biliary cirrhosis: follow-up for up to 28 years.
Topics: Aged; Cholagogues and Choleretics; Cohort Studies; Disease Progression; Female; Follow-Up Studies; Humans; Liver Cirrhosis, Biliary; Male; Middle Aged; Prevalence; Proportional Hazards Models; Risk Factors; United Kingdom; Ursodeoxycholic Acid | 2002 |
Ursodeoxycholic acid inhibits the initiation and postinitiation phases of azoxymethane-induced colonic tumor development.
Topics: Animals; Azoxymethane; Cholagogues and Choleretics; Colonic Neoplasms; Disease Models, Animal; Disease Progression; Dose-Response Relationship, Drug; Incidence; Male; Rats; Rats, Inbred F344; Time Factors; Treatment Outcome; Ursodeoxycholic Acid | 2002 |
Nodular regenerative hyperplasia of the liver: a rare differential diagnosis of cholestasis with response to ursodeoxycholic acid.
Topics: Biopsy; Cholestasis, Intrahepatic; Disease Progression; Female; Focal Nodular Hyperplasia; Humans; Liver; Liver Failure; Liver Function Tests; Liver Regeneration; Middle Aged; Treatment Outcome; Ursodeoxycholic Acid | 2003 |
[Sclerosing cholangitis as a complication of Langerhans'cell histiocytosis].
Topics: Abdominal Pain; Age Factors; Anti-Inflammatory Agents; Biopsy, Needle; Cholagogues and Choleretics; Cholangiopancreatography, Endoscopic Retrograde; Cholangitis, Sclerosing; Diabetes Insipidus; Disease Progression; Drug Therapy, Combination; Endosonography; Histiocytosis, Langerhans-Cell; Humans; Magnetic Resonance Imaging; Male; Middle Aged; Prednisone; Prognosis; Rare Diseases; Time Factors; Tomography, X-Ray Computed; Ursodeoxycholic Acid; Weight Loss | 2003 |
Ursodeoxycholic acid and histological progression in primary biliary cirrhosis.
Topics: Disease Progression; Humans; Liver Cirrhosis, Biliary; Ursodeoxycholic Acid | 2003 |
The effect of ursodeoxycholic acid therapy on the natural course of primary biliary cirrhosis.
Topics: Adult; Aged; Cholagogues and Choleretics; Disease Progression; Female; Humans; Liver Cirrhosis, Biliary; Male; Markov Chains; Middle Aged; Models, Biological; Multivariate Analysis; Survival Analysis; Ursodeoxycholic Acid | 2005 |
Demonstration of reversed flow in segmental branches of the portal vein with hand-held color Doppler ultrasonography after hematopoietic stem cell transplantation.
Topics: Adolescent; Adult; Aged; Child; Disease Progression; Female; Hematopoietic Stem Cell Transplantation; Hepatic Veno-Occlusive Disease; Humans; Hypertension, Portal; Liver Diseases; Male; Middle Aged; Portal Vein; Time Factors; Treatment Outcome; Ultrasonography; Ultrasonography, Doppler; Ursodeoxycholic Acid | 2005 |
Long term outcome and response to therapy of primary biliary cirrhosis-autoimmune hepatitis overlap syndrome.
Topics: Adult; Aged; Biopsy; Cholagogues and Choleretics; Disease Progression; Drug Therapy, Combination; Female; Follow-Up Studies; Glucocorticoids; Hepatitis, Autoimmune; Humans; Immunosuppressive Agents; Liver Cirrhosis, Biliary; Male; Middle Aged; Retrospective Studies; Syndrome; Time Factors; Treatment Outcome; Ursodeoxycholic Acid | 2006 |
Ursodeoxycholic acid in primary biliary cirrhosis improves glutathione status but fails to reduce lipid peroxidation.
Topics: Adult; Aged; Antioxidants; Dinoprost; Disease Progression; Female; gamma-Glutamyltransferase; Glutathione; Humans; Lipid Peroxidation; Liver; Liver Cirrhosis, Biliary; Male; Middle Aged; Ursodeoxycholic Acid | 2006 |
A lean man with nonalcoholic fatty liver disease.
Topics: Adult; Biopsy, Needle; Blood Chemical Analysis; Body Mass Index; Disease Progression; Fatty Liver; Follow-Up Studies; Humans; Immunohistochemistry; Liver Failure, Acute; Liver Function Tests; Liver Transplantation; Male; Thinness; Treatment Outcome; Ursodeoxycholic Acid | 2007 |
Primary sclerosing cholangitis: patients with a rising alkaline phosphatase at annual follow-up.
Topics: Alkaline Phosphatase; Bile Duct Neoplasms; Bile Ducts, Intrahepatic; Biomarkers, Tumor; Biopsy; CA-19-9 Antigen; Carcinoembryonic Antigen; Cholagogues and Choleretics; Cholangiocarcinoma; Cholangitis, Sclerosing; Colitis, Ulcerative; Diagnostic Imaging; Disease Progression; Humans; Male; Middle Aged; Practice Guidelines as Topic; Ursodeoxycholic Acid | 2007 |
Development of autoimmune hepatitis in primary biliary cirrhosis.
Topics: Adult; Alanine Transaminase; Anti-Inflammatory Agents; Aspartate Aminotransferases; Azathioprine; Cholagogues and Choleretics; Disease Progression; Drug Therapy, Combination; Female; Follow-Up Studies; Hepatitis, Autoimmune; Humans; Immunosuppressive Agents; Liver Cirrhosis, Biliary; Middle Aged; Prednisone; Retrospective Studies; Syndrome; Time Factors; Treatment Outcome; Ursodeoxycholic Acid | 2007 |
[Anicteric form of progressive familial intrahepatic cholestasis (Byler syndrome)].
Topics: Anti-Bacterial Agents; Cholagogues and Choleretics; Cholestasis, Intrahepatic; Dietary Supplements; Disease Progression; Female; Humans; Infant; Rifampin; Treatment Outcome; Ursodeoxycholic Acid; Vitamins | 2008 |
Prognostic factors and long-term effects of ursodeoxycholic acid on liver biochemical parameters in patients with primary biliary cirrhosis. Dutch Multi-Centre PBC Study Group.
Topics: Bilirubin; Cholagogues and Choleretics; Disease Progression; Dose-Response Relationship, Drug; Female; Humans; Liver Cirrhosis, Biliary; Liver Function Tests; Male; Middle Aged; Multivariate Analysis; Prognosis; Prospective Studies; Remission Induction; Treatment Outcome; Ursodeoxycholic Acid | 1999 |
Time course of histological progression in primary sclerosing cholangitis.
Topics: Adolescent; Adult; Aged; Biopsy; Cholagogues and Choleretics; Cholangitis, Sclerosing; Disease Progression; Female; Follow-Up Studies; Hepatitis; Humans; Liver; Liver Cirrhosis; Liver Cirrhosis, Biliary; Male; Markov Chains; Middle Aged; Necrosis; Penicillamine; Time Factors; Treatment Outcome; Ursodeoxycholic Acid | 1999 |
Changes of liver fibrosis in chronic hepatitis C patients with no response to interferon-alpha therapy: including quantitative assessment by a morphometric method.
Topics: Alanine Transaminase; Antiviral Agents; Biomarkers; Biopsy; Disease Progression; Drugs, Chinese Herbal; Female; Glycyrrhizic Acid; Hepatitis C; Hepatitis C, Chronic; Humans; Injections, Intramuscular; Interferon-alpha; Liver Cirrhosis; Male; Middle Aged; Peptide Fragments; Procollagen; Retrospective Studies; RNA, Viral; Ursodeoxycholic Acid | 2000 |
Clinical studies with silymarin: fibrosis progression is the end point.
Topics: Cholagogues and Choleretics; Disease Progression; Drug Therapy, Combination; Fibrosis; Humans; Liver Cirrhosis, Biliary; Protective Agents; Retreatment; Silymarin; Ursodeoxycholic Acid | 2001 |
Paradoxical progression of biliary strictures against recovery of biochemical parameters under ursodeoxycholic acid treatment in a case of primary sclerosing cholangitis with ulcerative colitis.
Topics: Adult; Anti-Inflammatory Agents; Antibodies, Antineutrophil Cytoplasmic; Autoimmune Diseases; Betamethasone; Bile Ducts; Biopsy; Cholangiopancreatography, Endoscopic Retrograde; Cholangitis, Sclerosing; Colitis, Ulcerative; Colonoscopy; Disease Progression; Drug Therapy, Combination; Humans; Immunosuppressive Agents; Liver; Liver Function Tests; Male; Mesalamine; Prednisolone; Ursodeoxycholic Acid | 2000 |
Rapid progress of acute suppurative cholangitis to secondary sclerosing cholangitis sequentially followed-up by endoscopic retrograde cholangiography.
Topics: Acute Disease; Aged; Bile Ducts, Intrahepatic; Cholagogues and Choleretics; Cholangiopancreatography, Endoscopic Retrograde; Cholangitis; Cholangitis, Sclerosing; Dilatation, Pathologic; Disease Progression; Humans; Male; Ursodeoxycholic Acid | 2001 |
Primary biliary cirrhosis: incidence and predictive factors of cirrhosis development in ursodiol-treated patients.
Topics: Bilirubin; Cholagogues and Choleretics; Disease Progression; Female; Humans; Incidence; Liver; Liver Cirrhosis, Biliary; Male; Markov Chains; Middle Aged; Multivariate Analysis; Necrosis; Predictive Value of Tests; Prognosis; Risk Factors; Serum Albumin; Ursodeoxycholic Acid | 2002 |